First-in-human Study of 7MW4911 in GI Cancer

Part of paid clinical trials in Port Saint Lucie, Florida.

Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Study ID
NCT07216560
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • GI Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 7MW4911 — DRUG
    study drug

Study Details

This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.

Key Dates

Start date
Jan 13, 2026
Status verified
Apr 2026
Primary completion
Jul 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 7MW4911

Primary Outcome Measure

Incidence and rates of adverse events [ Time Frame: Up to approximately 2 years ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Hematology Oncology Associates of the Treasure CoastPort Saint LucieFlorida34952
Kerlande Romeus
[email protected]
772-408-5157
Massachusetts General HospitalBostonMassachusetts02114
Ashley O'Meara
[email protected]
866-493-1612
STARTLong Island CityNew York11042
Sadia Morium
[email protected]
363-207-5160
START Moutain RegionWest Valley CityUtah84119
Raynard Bello
[email protected]
801-907-4750
+1(801)9074750
Fred Hutchinson Cancer CenterSeattleWashington98109
Isabel Blanco
[email protected]
206-606-6658

Find similar trials in Port Saint Lucie, FL

By research site
Hematology Oncology Associates of the Treasure Coast· Port Saint Lucie, FLMassachusetts General Hospital· Boston, MASTART· Long Island City, NYSTART Moutain Region· West Valley City, UTFred Hutchinson Cancer Center· Seattle, WA

Related Studies